Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis,

Shinto, L.; Marracci, G.; Baldauf-Wagner, S.; Strehlow, A.; Yadav, V.; Stuber, L.; Bourdette, D.

doi:10.1016/j.plefa.2008.12.001

« Previous Next »Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 80, Issue 2 , Pages 131-136, February 2009

Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsing-remitting multiple sclerosis^,☆☆☆

L. Shinto
- Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
- Corresponding author. Tel.: +15034945035; fax: +15034188373.
- L. Shinto and G. Marracci contributed equally to this work.
G. Marracci
- Department of Veterans Affairs Medical Center, Portland, OR, USA
- L. Shinto and G. Marracci contributed equally to this work.
S. Baldauf-Wagner
- Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
A. Strehlow
- Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
- Department of Veterans Affairs Medical Center, Portland, OR, USA
V. Yadav
- Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
- Department of Veterans Affairs Medical Center, Portland, OR, USA
L. Stuber
- Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
D. Bourdette
- Department of Neurology, Oregon Health & Science University (OHSU), 3181 SW Sam Jackson Park Road, CR120 Portland, OR 97239, USA
- Department of Veterans Affairs Medical Center, Portland, OR, USA

Received 15 May 2007; received in revised form 25 November 2008; accepted 15 December 2008. published online 25 August 2009.

Abstract

Objectives

The primary objective was to evaluate the effect of omega-3 fatty acids (omega-3 FA) on matrix metalloproteinase-9 (MMP-9) production by immune cells in multiple sclerosis (MS). Quality of life, fatty acid levels, and safety were also evaluated.

Materials and Methods

Ten participants with relapsing-remitting MS (RRMS) received omega-3 FA supplementation (9.6g/day fish oil) in an open-label study. Participants were evaluated at four time points, baseline, after 1 month of omega-3 FA supplementation, after 3 months of omega-3 FA supplementation, and after a 3-month wash out.

Results

Immune cell secretion of MMP-9 decreased by 58% after 3 months of omega-3 FA supplementation when compared with baseline levels (p<0.01). This effect was coupled with a significant increase in omega-3 FA levels in red blood cell membranes.

Conclusions

Omega-3 FA significantly decreased MMP-9 levels in RRMS and may act as an immune-modulator that has potential therapeutic benefit in MS patients.

Keywords: Omega-3 fatty acids, Multiple sclerosis, Matrix metalloproteinase

To access this article, please choose from the options below

☆ None of the authors have anything to disclose.

☆☆ This research was support by the National Institutes of Health P50 AT00066-01, the Department of Veterans Affairs, and the Nancy Davis Center Without Walls.

PII: S0952-3278(08)00189-0

doi:10.1016/j.plefa.2008.12.001

« Previous Next »Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 80, Issue 2 , Pages 131-136, February 2009

Access this article on SciVerse ScienceDirect